VJHemOnc Podcast

Épisodes

• 
  Using BTK inhibitors in lymphoma: practical considerations for community physicians 11.09.2026 22min

  This episode of the VJHemOnc podcast, featuring Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, focuses on the practical use of BTK inhibitors (BTKis) in non-Hodgkin lymphoma (NHL). Dr Kamdar begins by discussing which factors guide patient selection for BTKi therapy and outlines how to choose among available agents. She then shares valuable insights on toxicity management, approaching patients with cardiovascular comorbidities, and monitoring treatment response and progression. Finally, Dr Kamdar leaves community physicians with three practical takeaways for successfully using BTKis in everyday clinical practice.
• 
  AAV gene therapy in hemophilia: progress, challenges and what comes next 03.09.2026 24min

  This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of AAV-based approaches and the development of next-generation strategies. Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, discusses the limitations of AAV gene therapy in hemophilia A, including factor VIII engineering, durability, and liver toxicity. He also examines potential malignancy risks associated with AAV integration and the importance of long-term surveillance following treatment. Finally, Dr Kaczmarek discusses emerging non-AAV approaches, including lentiviral gene therapy, targeted gene insertion, and gene editing, and their potential to address some of the limitations of current gene therapy approaches.
• 
  Clinical considerations in MCL management: frailty assessment, the multidisciplinary team & managing the use of BTKis 26.08.2026 18min

  This VJHemOnc podcast explores the evolving management of mantle cell lymphoma (MCL), from assessing patient fitness to sequencing therapy after BTK inhibitor progression. Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, and Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, discuss assessing fitness and frailty, while Craig Portell, MD, University of Virginia, Charlottesville, VA, outlines the multidisciplinary approach to MCL care. Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, reviews frontline sequencing, including using MRD status to guide transplant decisions, and Dr Phillips and Dr Portell discuss managing patients with higher-risk disease features. Dr Portell also addresses toxicity and treatment burden with long-term BTK inhibitor use. To conclude, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Dr Karimi highlight emerging options after BTK inhibitor progression, including non-covalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, and bispecific antibodies.
• 
  Sequencing therapies in multiple myeloma: navigating an expanding treatment landscape 24.08.2026 24min

  This VJHemOnc podcast explores the evolving treatment landscape in multiple myeloma, focusing on treatment selection and sequencing across the disease course. Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses shared decision-making in frontline treatment, while Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, explores sequencing CAR T-cell therapies and bispecific antibodies, including the choice between BCMA- and GPRC5D-directed approaches. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, reviews updated findings from the MajesTEC-3 trial (NCT05083169) of teclistamab plus daratumumab in high-risk disease, and Peter Voorhees discusses Phase III MonumenTAL-3 (NCT05455320) data evaluating talquetamab plus daratumumab, with or without pomalidomide. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, highlights strategies for managing infections associated with bispecific antibodies, while Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the transition towards community-based delivery of bispecific therapies.
• 
  The evolving treatment landscape in ALL: the growing role of immunotherapy and reduced reliance on chemotherapy 14.08.2026 23min

  There has been a significant shift in the treatment of acute lymphoblastic leukemia (ALL), driven by the emergence of novel immunotherapies. In this episode, leading experts explore how these advances are changing the treatment landscape and where the field is headed next. First, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, outlines emerging treatment strategies for ALL and highlights the potential to reduce reliance on intensive chemotherapy by integrating novel therapies into clinical practice. Then, Martin Schrappe, MD, FRCP, University Medical Center Schleswig-Holstein, Kiel, Germany, shares insights into a trial evaluating blinatumomab as a replacement for high-dose chemotherapy in pediatric patients with newly diagnosed high-risk ALL. Following this, you will hear a discussion from the 8th International Workshop on CAR-T and Bispecifics, in which Ibrahim Aldoss, MD, City of Hope, Duarte, CA, and Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, provide updates on T-cell engagers and CAR T-cell therapy in ALL. To conclude the episode, Nicola Maciocia, MBChB, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses advances in CAR-T for T-cell ALL and comments on whether cellular immunotherapy may be the most promising approach to curing this leukemia subtype.
• 
  Precision medicine in MDS: tailoring treatment through molecular profiling 07.08.2026 19min

  This VJHemOnc podcast explores how precision medicine is reshaping the management of myelodysplastic syndromes (MDS). Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses whole genome sequencing, patient selection for venetoclax-based therapy, and the future of precision medicine following the VERONA trial (NCT04401748). Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, reviews the evolving role of luspatercept, while Sophie Park, MD, PhD, CHU Grenoble Alpes, Grenoble, France, presents Phase III EPO-PRETAR (NCT03223961) findings. Mika Kontro, MD, PhD, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, discusses updated BEXMAB trial (NCT05428969) results of bexmarilimab plus azacitidine. Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, explores TP53-mutated MDS, and Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights first-in-human data for the CLK inhibitor BH-30236 in relapsed or refractory AML and higher-risk MDS.
• 
  The current and future role of BTK inhibitors across non-Hodgkin lymphoma subtypes 23.07.2026 24min

  This episode of the VJHemOnc podcast explores the current and future role of BTK inhibition across several non-Hodgkin lymphoma (NHL) subtypes. First, Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, Steven Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA, and Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, provide insight into the established role of BTK inhibitors (BTKis) in Waldenström's macroglobulinemia (WM). Following this, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, discuss the shift of BTKis to the frontline setting in mantle cell lymphoma (MCL), and outline therapeutic approaches being evaluated for patients who relapse on these agents. Next, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, highlights why BTKis have not had the same impact in follicular lymphoma (FL) as in other B-cell malignancies, and comments on their current role in this disease, before Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the value of newer-generation BTK inhibitors in relapsed/refractory (R/R) indolent B-cell lymphoma. To conclude, Dr Kamdar shares insight into the potential role of BTKis in diffuse large B-cell lymphoma (DLBCL).
• 
  The diagnosis and management of hematologic malignancies during pregnancy 16.07.2026 17min

  In this episode of the VJHemOnc podcast, Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, shares insight into the diagnosis and management of hematologic malignancies during pregnancy. Dr Dierickx comments on common misconceptions clinicians may have when treating this patient population and outlines key principles and factors that guide clinical decisions for pregnant patients to optimize outcomes for both the mother and the baby. He then discusses the current approach to managing specific malignancies during gestation, including acute leukemias, Hodgkin and non-Hodgkin lymphoma, myeloproliferative neoplasms (MPNs), and multiple myeloma. 
• 
  Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse 10.07.2026 19min

  This VJHemOnc podcast explores the latest advances in Hodgkin lymphoma, from evolving frontline treatment strategies to emerging approaches in relapsed and refractory disease. Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the final three-year results from the AVENUE study (NCT03617666) and the role of circulating tumor DNA (ctDNA) in guiding treatment de-escalation. Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, compares BrECADD and Nivo-AVD for advanced-stage disease, while Sven Borchmann, MD, University Hospital Cologne, Cologne, Germany, highlights the prognostic value of ctDNA-based measurable residual disease assessment. Guilherme Perini, MD, Hospital Israelita Albert Einstein, São Paulo, Brazil, reviews the Phase II KEYFORM-008 trial (NCT05508867) investigating dual LAG-3 and PD-1 blockade in relapsed or refractory classical Hodgkin lymphoma, and Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James's University Hospital, Leeds, UK, discusses treatment sequencing after checkpoint inhibition and the evolving role of autologous stem cell transplantation.
• 
  Sequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies 30.06.2026 19min

  This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment options following covalent BTK inhibitor therapy, including venetoclax-based regimens and non-covalent BTK inhibitors. Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, examines treatment selection after BTK inhibitor therapy, the improved safety profile of second-generation BTK inhibitors, and the Phase III AMPLIFY trial (NCT03836261) evaluating fixed-duration acalabrutinib plus venetoclax. Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, reviews the CLL-FRAIL study investigating continuous acalabrutinib in older and frail patients with CLL. Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses strategies to overcome BTK inhibitor resistance, including fixed-duration combinations and long-term follow-up from a Phase II study of venetoclax plus ibrutinib in patients with BTK inhibitor resistance mutations. Finally, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, presents findings from the Phase III BRUIN CLL-322 trial (NCT06073821) evaluating fixed-duration pirtobrutinib, venetoclax, and rituximab in previously treated CLL.
• 
  Precision medicine in AML: from targeted therapy to transplantation 22.06.2026 19min

  This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted therapies, measurable residual disease (MRD) assessment, and transplantation. Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the Phase I/II KOMET-007 study (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy for newly diagnosed NPM1-mutated or KMT2A-rearranged AML, while Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, reviews the emerging menin inhibitor landscape. Robert Negrin, MD, Stanford University, Stanford, CA, discusses the selection of FLT3 inhibitors and the role of FLT3-directed maintenance following allogeneic stem cell transplantation. Jorge Cortes, MD, University of Alabama at Birmingham, Birmingham, AL, presents a quality-adjusted survival analysis of quizartinib in newly diagnosed FLT3-ITD-positive AML. Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, explores the integration of targeted therapies, mutation status, and MRD assessment into transplant decision-making. Finally, Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses revumenib maintenance after transplantation in patients with KMT2A-rearranged or NPM1-mutated AML.
• 
  MPNs in focus: disease progression, risk assessment, and emerging treatments 15.06.2026 20min

  This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses mechanisms of disease progression, the DUSP6-RSK1 signaling pathway as a therapeutic target, and the ongoing debate around early versus late intervention in MPNs. Hélène Gleitz, PhD, Erasmus MC, Rotterdam, Netherlands, shares insights into the role of the bone marrow microenvironment and fibrotic niches in disease evolution. Akriti Jain, MD, Cleveland Clinic, Cleveland, OH, discusses the prognostic significance of TP53 mutation acquisition timing, while Yu-Hung Wang, MD, PhD, National Taiwan University Cancer Center, Taipei City, Taiwan, highlights machine learning approaches that model MPNs as a biological continuum. Ciro Rinaldi, MD, PhD, United Lincolnshire Teaching Hospital and University of Lincoln, Lincoln, UK, reviews a Phase II study of momelotinib plus bomedemstat in myelofibrosis, and Marta Sobas, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, discusses ongoing unmet needs and future priorities in MPN care.
• 
  The evolving role of cellular therapies and T-cell engagers in lymphoma 29.05.2026 19min

  This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, to discuss novel cellular therapy strategies, including NK-cell therapies, allogeneic CAR T-cells, and in vivo CAR approaches. The panel highlights early clinical data with the iPSC-derived NK-cell products FT516 and FT596, alongside evolving strategies to reduce CAR T-cell toxicity and improve access to cellular therapies. The podcast also features Loretta Nastoupil, MD, Southwest Oncology, Durango, CO, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the expanding role of T-cell engagers in follicular lymphoma and large B-cell lymphoma, including mosunetuzumab-based combinations and the growing number of frontline bispecific antibody trials in diffuse large B-cell lymphoma.
• 
  Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure 22.05.2026 20min

  This VJHemOnc podcast explores how evolving treatment strategies, immunotherapies, and MRD-driven approaches are reshaping the management of multiple myeloma and precursor disease. Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses early intervention strategies in smoldering myeloma and presents findings from the CAR-PRISM study (NCT05767359) evaluating cilta-cel in high-risk smoldering disease. Kwee Yong, MD, PhD, FRCP, FRCPath, University College London, London, UK, highlights advances in understanding the genomic and immune drivers of progression in smoldering myeloma. Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, The Netherlands, reviews evolving frontline treatment strategies, including quadruplet regimens, combination maintenance, and the growing role of sustained MRD negativity. Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses BCMA-targeted therapies, including findings from the DREAMM-6 (NCT03544281) and REALiTEC-2 (NCT06285318) studies evaluating belantamab mafodotin and teclistamab in relapsed/refractory multiple myeloma. Finally, Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, explores evolving concepts of cure and the role of sustained MRD negativity in defining long-term remission in multiple myeloma.
• 
  Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy 15.05.2026 25min

  This VJHemOnc podcast features a roundtable discussion from the 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) 2026 on the evolving role of dual-targeting CAR T-cell therapies in large B-cell lymphoma (LBCL). Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, is joined by Saurabh Dahiya, MD, FACP, Stanford University School of Medicine, Stanford, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, and Akil Merchant, MD, Cedars-Sinai Medical Center, Los Angeles, CA, to discuss recent trial updates evaluating dual-targeting CAR constructs in LBCL. The discussion highlights efficacy and safety outcomes, as well as key challenges in clinical practice, including rapid manufacturing, the role of bridging therapy, toxicity management, and optimizing patient selection. The panel also reflects on the importance of interpreting CAR T-cell trial results within the context of differing study designs and inclusion criteria.
• 
  Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation 08.05.2026 17min

  This VJHemOnc podcast explores the latest advances in gene-based therapies for sickle cell disease (SCD) and thalassemia, highlighting progress in patient access, selection, treatment delivery, and clinical outcomes. Sunil Gupta, MD, FRCP, FRCPath, MBA, Lewisham and Greenwich NHS Trust, London, UK, discusses expanding access to gene therapy for patients with SCD, while Alexander Ngwube, MD, Baylor College of Medicine, Houston, TX, shares insights into real-world patient selection and decision-making. Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, outlines key considerations for selecting patients with SCD and thalassemia for gene therapy, discusses strategies to optimize the treatment pathway from stem cell mobilization to long-term follow-up, and reviews results from the RUBY trial (NCT04853576) of gene editing therapy in severe SCD. Zachary Crees, MD, Washington University School of Medicine, St. Louis, MO, also highlights emerging mobilization approaches, including motixafortide-based strategies to improve stem cell collection for gene therapy.
• 
  The evolving role of BTK inhibitors in CLL 01.05.2026 25min

   
• 
  Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians 24.04.2026 19min

  In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the main factors contributing to the observed reduction in the incidence of higher-grade CRS and ICANS following CAR-T. Following this, Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, shares insight into infection prevention and antibiotic use in febrile patients, and Birte Friedrichs, MD, Düsseldorf University Hospital, Düsseldorf, Germany, discusses the misconception among physicians that the side effects of CAR-T are too severe for their patients, noting the potential impact of this belief. You will then hear from Megan Melody, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, who shares advice for community physicians monitoring patients for less common toxicities following CAR-T, and Kenneth Lim, MBBS, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, who highlights AEs that physicians should be aware of when treating patients with multiple myeloma with ciltacabtagene autoleucel (cilta-cel).
• 
  The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care 16.04.2026 13min

  This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chemo‑free regimens and the growing role of BTK inhibitors. Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of frontline treatment in achieving long-term disease control. You will also hear from David Lewis, MBChB, PhD, FRCPath, Plymouth University, Plymouth, UK, Tycel Phillips, MD, City of Hope, Duarte, CA, and Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, who share perspectives on patient selection for therapy, biological risk factors, and how treatment decisions differ between academic and community settings.
• 
  Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies 09.04.2026 21min

  This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents.Experts discuss the growing importance of donor germline genetics, updated guidance for Hodgkin lymphoma transplantation, the shifting role of CAR T‑cell therapy in non‑Hodgkin lymphoma, and how measurable residual disease (MRD) is shaping transplant decisions and post‑transplant care.Overall, the episode highlights how these developments are improving personalization and outcomes in haemopoietic stem cell transplantation.